172 related articles for article (PubMed ID: 37230161)
21. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
22. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
Tap SC
Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
[TBL] [Abstract][Full Text] [Related]
23. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.
Barker SA; McIlhenny EH; Strassman R
Drug Test Anal; 2012; 4(7-8):617-35. PubMed ID: 22371425
[TBL] [Abstract][Full Text] [Related]
24. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
[TBL] [Abstract][Full Text] [Related]
25. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
[TBL] [Abstract][Full Text] [Related]
26. The Psilocin (4-hydroxy-N,N-dimethyltryptamine) and Bufotenine (5-hydroxy-N,N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been Identified.
Mishraki-Berkowitz T; Kochelski E; Kavanagh P; O'Brien J; Dunne C; Talbot B; Ennis P; Wolf UE
J Forensic Sci; 2020 Sep; 65(5):1450-1457. PubMed ID: 32374425
[TBL] [Abstract][Full Text] [Related]
27. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
Halberstadt AL; Nichols DE; Geyer MA
Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
[TBL] [Abstract][Full Text] [Related]
28. The indole hallucinogens, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), have different effects from mescaline on rat shuttlebox avoidance.
Stoff DM; Gorelick DA; Bozewicz T; Bridger WH; Gillin JC; Wyatt RJ
Neuropharmacology; 1978 Dec; 17(12):1035-40. PubMed ID: 284199
[No Abstract] [Full Text] [Related]
29. Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS.
Forsström T; Tuominen J; Karkkäinen J
Scand J Clin Lab Invest; 2001; 61(7):547-56. PubMed ID: 11763413
[TBL] [Abstract][Full Text] [Related]
30. Unlocking the biosynthesis of psychedelic-inspired indolethylamines.
Sen AK; Jones JA
Trends Biochem Sci; 2024 Mar; 49(3):189-191. PubMed ID: 38160063
[TBL] [Abstract][Full Text] [Related]
31. Plants and mushrooms of abuse.
Spoerke DG; Hall AH
Emerg Med Clin North Am; 1990 Aug; 8(3):579-93. PubMed ID: 2201522
[TBL] [Abstract][Full Text] [Related]
32. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
J Psychopharmacol; 2024 Apr; ():2698811241246857. PubMed ID: 38616411
[TBL] [Abstract][Full Text] [Related]
33. Opposite effects of N,N-dimethyltryptamine (DMT) and 5-methoxy-n,n-dimethyltryptamine (5-MeODMT) on acoustic startle: spinal vs brain sites of action.
Commissaris RL; Davis M
Neurosci Biobehav Rev; 1982; 6(4):515-20. PubMed ID: 6817240
[TBL] [Abstract][Full Text] [Related]
34. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
[TBL] [Abstract][Full Text] [Related]
35. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
Lancelotta RL; Davis AK
J Psychoactive Drugs; 2020; 52(3):273-281. PubMed ID: 32148190
[TBL] [Abstract][Full Text] [Related]
36. Indolethylamine-
Dean JG
Front Neurosci; 2018; 12():232. PubMed ID: 29740267
[No Abstract] [Full Text] [Related]
37. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.
Shen HW; Jiang XL; Yu AM
Drug Metab Dispos; 2011 Jul; 39(7):1227-34. PubMed ID: 21464174
[TBL] [Abstract][Full Text] [Related]
38. Indolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in rats.
Glynos NG; Carter L; Lee SJ; Kim Y; Kennedy RT; Mashour GA; Wang MM; Borjigin J
Sci Rep; 2023 Jan; 13(1):280. PubMed ID: 36609666
[TBL] [Abstract][Full Text] [Related]
39. A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation.
Callaway JC; Grob CS; McKenna DJ; Nichols DE; Shulgin A; Tupper KW
J Anal Toxicol; 2006; 30(6):406-7; author reply 407. PubMed ID: 16872575
[No Abstract] [Full Text] [Related]
40. Evidence for and against the involvement of N,N-dimethyl-tryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in schizophrenia.
Gillin JC; Wyatt RJ
Psychopharmacol Bull; 1976 Oct; 12(4):12-3. PubMed ID: 1067623
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
